The rare aggressive pituitary adenoma presents a special challenge, due to the heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas has been improved due to recent studies demonstrating clinically-relevant efficacy of temozolomide, which is now considered first-line chemotherapy. However, there is limited data on second-line therapies in patients with treatment failure. This review presents a summary on the potential of medical therapies in aggressive pituitary tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-1331-6939 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!